BGPT: Paper Review: Review of two immunosuppressants: tacrolimus and cyclosporine

Explore by Goal

Quick Explanation Copied

Paper reviewed:

“Review of two immunosuppressants: tacrolimus and cyclosporine” (J Korean Assoc Oral Maxillofac Surg, DOI: 10.5125/jkaoms.2023.49.6.311).

Core claims are mechanistic (calcineurin/CNIs), comparative (tacrolimus: less acute rejection; similar graft survival), safety (nephrotoxicity/neurotoxicity; different metabolic/toxicity patterns), and a niche section on nerve regeneration plus facial transplantation context.

Long Explanation

Critical visual review: Tacrolimus vs Cyclosporine

“Review of two immunosuppressants: tacrolimus and cyclosporine” (DOI: 10.5125/jkaoms.2023.49.6.311)

Evidence hierarchy note: this is a review article summarizing other studies, not original trial data.

1) What the paper sets out to do

Compare mechanisms, efficacy, and safety of tacrolimus vs cyclosporine; discuss “alternatives” aiming to mitigate CNI toxicity.
Contextualize importance for organ transplantation and specifically facial transplantation.

2) Methods transparency (and where it may be weak)

Search and screening: PubMed + Google Scholar; total identified 1,442; duplicates removed; full-text screen leading to 84 included.

Inclusion/exclusion: excludes non-English, duplicates, pediatric, animal studies, case reports/letters, and non-transplant indications.

Bias risk flag: the paper explicitly includes only English and excludes animal studies, yet still discusses nerve regeneration properties using animal studies in the narrative. That tension is an internal methodological inconsistency worth scrutinizing.

3) Mechanism of action: calcineurin inhibition (what is solid)

3.1 Shared core mechanism

Both drugs function as calcineurin inhibitors, suppressing T-cell activation via blockade of NFAT nuclear translocation and reduced IL-2 transcription.
Cyclosporine’s immunopharmacology includes calcineurin/NFAT blockade and also MAPK pathway effects (p38/JNK described as blocked upstream in the paper’s schematic narrative).

3.2 A mechanistic diagram you can reuse mentally

The paper includes a calcineurin inhibitor pathway schematic (Fig. 3).

4) Comparative efficacy & safety (numerical signals extracted from text)

The paper reports several quantitative comparisons; below are “as-stated” numeric extractions (not re-calculated from raw trial datasets).

Source for numbers: paper’s reported values for Krämer et al.

Source for numbers: paper’s reported 3- and 5-year graft survival rates (with P<0.01).

Source for numbers: paper’s stated diabetes prevalence 20% vs 4%.

4.1 Safety: nephrotoxicity and neurotoxicity (knowns vs unknowns)

Both are associated with nephrotoxicity (acute and chronic forms).
Nephrotoxicity mechanistic framing is aligned with a foundational review: Naesens et al.
The paper explicitly says it is not clear which drug carries greater nephrotoxicity risk and discusses how route/formulation and older studies may have biased comparisons.
Neurotoxicity: paper lists posterior reversible leukoencephalopathy syndrome, akinetic mutism, toxic encephalopathy, seizures, and notes tacrolimus tends to have higher neurologic complication rates (e.g., tremor/paresthesia/insomnia), especially in liver transplant recipients.
This aligns with a broader neurotoxicity review literature.

Skeptical note

The numeric comparisons above come from cited studies summarized by this review. Clinical conclusions therefore depend on: study era, background regimens, endpoints used (e.g., biopsy-proven rejection vs clinical), dosing/therapeutic drug monitoring practices, and crossover rules.

5) “Nerve regeneration” claim: likely mechanistic interest, but evidence-grade is mixed

The paper contrasts tacrolimus vs cyclosporine peripheral nerve regenerative effects, largely based on animal studies and mechanistic hypotheses (e.g., FKBP-12/TGF-β1 pathway; growth cone effects).

Important limitation: this plot is qualitative and directly reflects the review’s directional claim, not magnitude from a meta-analysis.

Mechanistic hypotheses (FKBP-12, FKBP-52) noted

Paper proposes FKBP-12-mediated TGF-β1 pathway activation with NGF synthesis as one explanation.
Another cited mechanistic paper argues FKBP-52 (not FKBP-12) can mediate FK506 neurotrophic action.
Because the mechanistic literature points to more than one candidate immunophilin path, the causal pathway for “nerve regeneration in humans with tacrolimus” remains uncertain based on this review alone.

6) Alternatives to CNIs: overview of tradeoffs (GFR vs rejection/infection risks)

The paper describes conversion/avoidance strategies using MMF, mTOR inhibitors (sirolimus/everolimus), and belatacept, emphasizing that nephrotoxicity may be reduced but other adverse outcomes (e.g., acute rejection) can increase.

This diagram intentionally avoids “fake precision”: it encodes only the review’s stated directionality of tradeoffs, not numeric effect estimates.

7) Critical appraisal (skeptical, evidence-based)

7.1 Strengths

Mechanism section is coherent with established calcineurin inhibitor biology (immunophilin binding → calcineurin phosphatase inhibition → NFAT/IL-2 suppression).
Safety concerns (nephrotoxicity + neurotoxicity) match broader clinical-nephrology/neurotoxicity reviews.
It acknowledges uncertainty in comparative nephrotoxicity risk (“not clear which carries greater risk”), which is epistemically better than making a single definitive winner.

7.2 Limitations / potential blind spots

Review-of-a-review problem: quantitative comparisons are extracted from heterogeneous studies; without uniform meta-analytic handling, “winner-takes-all” messaging can overstate certainty.
Internal methodological tension: exclusion of animal studies is stated, but nerve regeneration discussion cites animal experiments—this undermines strict reproducibility of how evidence was assembled.
Outcome definition variability: “acute rejection” can differ by protocol and era (clinical vs biopsy-proven), and the paper reports both qualitative and quantitative results from different trial types; this can be confounded by background immunosuppressant regimens.
Attribution risk: facial/vascularized composite allotransplant claims depend on small case series and multi-drug regimens; attributing nerve sensation recovery specifically to tacrolimus is mechanistically plausible but not strictly proven.

7.3 What would most disprove or change the paper’s high-level stance?

Consistent large, methodologically comparable RCT/meta-analytic evidence showing no acute rejection advantage for tacrolimus (or equivalently strong evidence that any advantage is offset by equal/greater long-term harm).
Robust translational evidence in humans that tacrolimus’s peripheral nerve effects are real and clinically meaningful, not just mechanistic/animal signals.
Stronger resolution of nephrotoxicity “who is worse” across comparable dosing routes/formulations with modern therapeutic monitoring.

8) Quick “what to remember” (evidence-weighted)

Established: both are calcineurin inhibitors affecting T-cell activation through NFAT/IL-2 suppression.
Comparative (as summarized): tacrolimus is associated with lower acute rejection in some comparisons, with graft survival broadly comparable but sometimes numerically better in follow-up rates reported by included studies.
Safety tradeoffs: both nephrotoxic; tacrolimus often has higher neurotoxicity rates and higher diabetogenic effects per the review’s synthesis; cyclosporine has metabolic/cosmetic side effects highlighted in the paper.
Nerve regeneration: mechanistically interesting but evidence is partly preclinical; human attribution remains uncertain.

Author reviews (open perspectives)

Feedback:

Updated: April 10, 2026